References
- World Health Organization, Cardiovascular diseases (CVDs), July 2024; https://www.who.int/europe/news-room/fact-sheets/item/cardiovascular-diseases; last access date November 4, 2024.
- EUROSTAT, Population Structure and Ageing, February 2024; https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Population_structure_and_ageing; last access date July 25, 2024.
- M. E. Tinetti, T. R. Fried and C. M. Boyd, Designing health care for the most common chronic condition–multimorbidity, JAMA 307(23) (2012) 2493–2494; https://doi.org/10.1001/jama.2012.5265
- S. M. Dunlay and A. M. Chamberlain, Multimorbidity in older patients with cardiovascular disease, Curr. Cardiovasc. Risk Rep. 10 (2016) Article ID 3; https://doi.org/10.1007/s12170-016-0491-8
- V. J. Wirtz, W. A. Kaplan, G. F. Kwan and R. O. Laing, Access to medications for cardiovascular diseases in low- and middle-income countries, Circulation 133(21) (2016) 2076–2085; https://doi.org/10.1161/CIRCULATIONAHA.115.008722
- D. P. Chew, I. A. Scott, L. Cullen, J. K. French, T. G. Briffa, P. A. Tideman, S. Woodruffe, A. Kerr, M. Branagan and P. E. Aylward; NHFA/CSANZ ACS Guideline 2016 Executive Working Group: National Heart Foundation of Australia & Cardiac Society of Australia and New Zealand, Australian clinical guidelines for the management of acute coronary syndromes, Heart Lung Circ. 25 (2016) 895–951; https://doi.org/10.1016/j.hlc.2016.06.789
- J. Tamargo, K. P. Kjeldsen, E. Delpón, A. G. Semb, E. Cerbai, D. Dobrev, G. Savarese, P. Sulzgruber, G. Rosano, C. Borghi, S. Wassmann, C. T. Torp-Pedersen, S. Agewall, H. Drexel, I. Baumgartner, B. Lewis, C. Ceconi, J. C. Kaski and A. Niessner, Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy, Eur. Heart J. Cardiovasc. Pharmacother. .(4) (2022) 406–419; https://doi.org/10.1093/ehjcvp/pvac005
- G. Crescioli, A. Bettiol, R. Bonaiuti, M. Tuccori, M. Rossi, A. Capuano, S. Pagani, G. Spada, M. Venegoni, G. D. Vighi, G. Mannaioni, A. Vannacci and N. Lombardi, MEREAFaPS Study group, Risk of hospitalization associated with cardiovascular medications in the elderly italian population: A nationwide multicenter study in emergency departments, Front. Pharmacol. 11 (2021) Article ID 611102 (11 pages); https://doi.org/10.3389/fphar.2020.611102
- C. Paradissis, N. Cottrell, I. Coombes, I. Scott, W. Wang and M. Barras, Patient harm from cardiovascular medications, Ther. Adv. Drug. Saf. 12 (2021) 1–22; https://doi.org/10.1177/20420986211027451
- T. J. Oscanoa, F. Lizaraso and A. Carvajal, Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis, Eur. J. Clin. Pharmacol. 73(6) (2017) 759–770; https://doi.org/10.1007/s00228-017-2225-3
- World Health Organization, The third WHO global patient safety challenge: Medication without harm, 2019; https://www.who.int/patientsafety/medication-safety/en/; last access date July 29, 2024.
- National Institute for Health and Clinical Excellence (NICE), Medicines optimisation: The safe and effective use of medicines to enable the best possible outcomes, March 2015; https://www.nice.org.uk/guidance/ng5, last access date July 25, 2024.
- Pharmaceutical Society of Australia, Medicine safety to be the 10th National Health Priority area, 2019; https://www.psa.org.au/, last access date July 25, 2024.
- The Joint Commission, National Patient Safety Goals, https://www.jointcommission.org/standards/national-patient-safety-goals/, 2024; last access date July 20, 2024.
- Institute for Safe Medication Practices, Highalert medications in acute care settings, 2018; https://www.ismp.org/recommendations/high-alertmedications-acute-list; last access date July 20, 2024.
- F. Salvi, A. Marchetti, F. D’Angelo, M. Boemi, F. Lattanzio and A. Cherubini, Adverse drug events as a cause of hospitalization in older adults, Drug Saf. 35(1) (2012) 29–45; https://doi.org/10.1007/BF03319101
- C. Cahir, Curran C. Curran, C. Walsh, A. Hickey, R. Brannigan, C. Kirke, D. J. Williams and K. Bennett, Adverse drug reactions in an ageing PopulaTion (ADAPT) study: Prevalence and risk factors associated with adverse drug reaction-related hospital admissions in older patients, Front Pharmacol. 13 (2023) Article ID 1029067 (10 pages); https://doi.org/10.3389/fphar.2022.1029067
- J. G. Naples, J. T. Hanlon, K. E. Schmader and T. P. Semla, Recent literature on medication errors and adverse drug events in older adults, J. Am. Geriatr. Soc. 64(2) (2016) 401–408; https://doi.org/10.1111/jgs.13922
- M. Tissot, M. B. Valnet-Rabier, T. Stalder, S. Limat, S. Davani and V. Nerich, Epidemiology and economic burden of “serious” adverse drug reactions: Real-world evidence research based on pharmacovigilance dana, Therapie 77(3) (2022) 291–300; https://doi.org/10.1016/j.therap.2021.12.007
- K. Dalton and S. Byrne, Role of the pharmacist in reducing healthcare costs: current insights, Integr. Pharm. Res. Pract. . (2017) 37–46; https://doi.org/10.2147/IPRP.S108047
- M. Jermini, C. Fonzo-Christe, K. Blondon, C. Milaire, J. Stirnemann, P. Bonnabry and B. Guignard, Financial impact of medication reviews by clinical pharmacists to reduce in-hospital adverse drug events: a return-on-investment analysis, Int. J. Clin. Pharm. 46(2) (2024) 496–505; https://doi.org/10.1007/s11096-023-01683-w
- L. Magro, E. Arzenton, R. Leone, M. G. Stano, M. Vezzaro, A. Rudolph, I. Castagna and U. Moretti, Identifying and characterizing serious adverse drug reactions associated with drug-drug interactions in a spontaneous reporting database, Front. Pharmacol. 11 (2021) Article ID 622862 (9 pages); https://doi.org/10.3389/fphar.2020.622862
- C. S. Moura, F. A. Acurcio and N. O. Belo, Drug-drug interactions associated with length of stay and cost of hospitalization, J. Pharm. Pharm. Sci. 12(3) (2009) 266–272; https://doi.org/10.18433/j35c7z
- J. P. Schmitt, A. Kirfel, M. T. Schmitz, H. Kohlhof, T. Weisbarth and M. Wittmann, The impact of drug interactions in patients with community-acquired pneumonia on hospital length of stay, Geriatrics (Basel) .(1) (2022) Article ID 11 (9 pages); https://doi.org/10.3390/geriatrics7010011
- L. Zerah, S. Henrard, I. Wilting, D. O’Mahony, N. Rodondi, O. Dalleur, K. Dalton, W. Knol, M. Haschke and A. Spinewine, Prevalence of drug-drug interactions in older people before and after hospital admission: analysis from the OPERAM trial, BMC Geriatr. 21(1) (2021) Article ID 571 (11 pages); https://doi.org/10.1186/s12877-021-02532-z
- T. Roblek, T. Vaupotic, A. Mrhar and M. Lainscak, Drug-drug interaction software in clinical practice: a systematic review, Eur. J. Clin. Pharmacol. 71(2) (2015) 131–142; https://doi.org/10.1007/s00228-014-1786-7
- R Core Team: A language and environment for statistical computing. R Foundation for Statistical Computing, 2018; https://www.R-project.org/; last access date 20 July 2024.
- B. Guthrie, B. Makubate, V. Hernandez-Santiago and T. Dreischulte, The rising tide of polypharmacy and drug–drug interactions: population database analysis 1995–2010, BMC Med. 13 (2015) Article ID 74 (10 pages); https://doi.org/10.1186/s12916-015-0322-7
- K. Barnett, S. W. Mercer, M. Norbury, G. Watt, S. Wyke and B. Guthrie, Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study, Lancet 380(9836) (2012) 37–43; https://doi.org/10.1016/S0140-6736(12)60240-2
- M. Petrovic, T. van der Cammen and G. Onder, Adverse drug reactions in older people: detection and prevention, Drugs Aging 29(6) (2012) 453–462; https://doi.org/10.2165/11631760-000000000-00000
- J. E. Hughes, V. Russo, C. Walsh, E. Menditto, K. Bennett and C. Cahir, Prevalence and factors associated with potential drug-drug interactions in older community-dwelling adults: A prospective cohort study, Drugs Aging 38(11) (2021) 1025–1037; https://doi.org/10.1007/s40266-021-00898-8
- L. A. Stevens, J. Coresh, T. Greene and A. S. Levey, Assessing kidney function – measured and estimated glomerular filtration rate, N. Engl. J. Med. 354(23) (2006) 2473–2483; https://doi.org/10.1056/NEJMra054415
- N. M. P. Maideen, Adverse effects associated with long-term use of proton pump inhibitors, Chonnam Med. J. 59(2) (2023) 115–127; https://doi.org/10.4068/cmj.2023.59.2.115
- Center for Drug Evaluation and Research, Clinical Drug Interaction Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions Guidance for Industry, January 2020; https://www.fda.gov/regulatory-information/search-fda-guidance-documents/clinical-drug-interaction-studies-cyto-chrome-p450-enzyme-and-transporter-mediated-drug-interactions; last access date July 10, 2024.
- US Food & Drug Administration, Drug Development and Drug Interactions: Table of Substrates, Inhibitors and Inducers, June 2023; https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers; last access date July 10, 2024.
- S. F. B. van der Horst, E. S. L. Martens, P. L. den Exter, M. H. A. Bos, T. E. van Mens, M. V. Huisman and F. A. Klok, Idarucizumab for dabigatran reversal: A systematic review and meta-analysis of indications and outcomes, Thromb. Res. 228 (2023) 21–32; https://doi.org/10.1016/j.thromres.2023.05.020
- S. J. Connolly, M. Sharma, A. T. Cohen, A. M. Demchuk, A. Członkowska, A. G. Lindgren, C. A. Molina, D. Bereczki, D. Toni, D. J. Seiffge, D. Tanne, E. C. Sandset, G. Tsivgoulis, H. Christensen, J. Beyer-Westendorf, J. M. Coutinho, M. Crowther, P. Verhamme, P. Amarenco, R. O. Roine, R. Mikulik, R. Lemmens, R. Veltkamp, S. Middeldorp, T. G. Robinson, T. J. Milling Jr, V. Tedim-Cruz, W. Lang, A. Himmelmann, P. Ladenvall, M. Knutsson, E. Ekholm, A. Law, A. Taylor, T. Karyakina, L. Xu, K. Tsiplova, S. Poli, B. Kallmünzer, C. Gumbinger and A. Shoamanesh; ANNEXA-I Investigators, Andexanet for factor Xa inhibitor-associated acute intracerebral hemorrhage, N. Engl. J. Med. 390(19) (2024) 1745–1755; https://doi.org/10.1056/NEJMoa2313040
- M. Kovačević, S. Vezmar Kovačević, B. Miljković, S. Radovanović and P. Stevanović, The prevalence and preventability of potentially relevant drug-drug interactions in patients admitted for cardiovascular diseases: A cross-sectional study, Int. J. Clin. Pract. 71(10) (2017) Article ID e13005 (9 pages); https://doi.org/10.1111/ijcp.13005
- I. Marinović, V. Bačić Vrca, I. Samardžić, S. Marušić and I. Grgurević, Potentially inappropriate medications involved in drug-drug interactions at hospital discharge in Croatia, Int. J. Clin. Pharm. 43(3) (2021) 566–576; https://doi.org/10.1007/s11096-020-01164-4
- I. Samardžić, I. Marinović, N. Kuča and V. Bačić Vrca, Potential clinically significant drug-drug interactions in prescribed pharmacotherapy in an outpatient setting, Pharmazie 76(8) (2021) 390–395; https://doi.org/10.1691/ph.2021.1561
- T. Roblek, A. Deticek, B. Leskovar, S. Suskovic, M. Horvat, A. Belic, A. Mrhar and M. Lainscak, Clinical-pharmacist intervention reduces clinically relevant drug-drug interactions in patients with heart failure: A randomized, double-blind, controlled trial, Int. J. Cardiol. 203 (2016) 647–652; https://doi.org/10.1016/j.ijcard.2015.10.206
- A. Rivkin and H. Yin, Evaluation of the role of the critical care pharmacist in identifying and avoiding or minimizing significant drug-drug interactions in medical intensive care patients, J. Crit. Care 26(1) (2011) Article ID 104.e1-104.e1046 (6 pages); https://doi.org/10.1016/j.jcrc.2010.04.014
- S. Vik, P. Weidemann, I. E. M. Gangås, S. E. Knapstad and S. Haavik, Pharmaceutical interventions on prescriptions in Norwegian community and hospital pharmacies, Int. J. Clin. Pharm. 43(4) (2021) 872–877; https://doi.org/10.1007/s11096-020-01188-w
- I. A. Scott, S. N. Hilmer, E. Reeve, K. Potter, D. Le Couteur, D. Rigby, D. Gnjidic, C. B. Del Mar, E. E. Roughead, A. Page, J. Jansen and J. H. Martin, Reducing inappropriate polypharmacy: The process of deprescribing, JAMA Intern. Med. 175(5) (2015) 827–834; https://doi.org/10.1001/jamainternmed.2015.0324
- I. A. Scott, S. N. Hilmer and D. G. Le Couteur, Going beyond the guidelines in individualising the use of antihypertensive drugs in older patients, Drugs Aging 36(8) (2019) 675–685; https://doi.org/10.1007/s40266-019-00683-8
- E. Reeve, Deprescribing tools: A review of the types of tools available to aid deprescribing in clinical practice, J. Pharm. Pract. Res. 50 (2020) 98–107; https://doi.org/10.1002/jppr.1626
- E. Reeve, V. Jordan, W. Thompson, M. Sawan, A. Todd, T. M. Gammie, I. Hopper, S. N. Hilmer and D. Gnjidic, Withdrawal of antihypertensive drugs in older people, Cochrane Database Syst. Rev. .(6) (2020) Article ID CD012572 (61 pages); https://doi.org/10.1002/14651858.CD012572.pub2
- J. P. Sheppard, A. Benetos and R. J. McManus, Antihypertensive deprescribing in older adults: A practical guide, Curr. Hypertens. Rep. 24(11) (2022) 571–580; https://doi.org/10.1007/s11906-022-01215-3